as the emergence of azole-resistance. This clinical reality creates an urgency for new antifungal drugs currently in advanced clinical development with more promising pharmacokinetic and pharmacodynamic profiles.

1. Introduction
Invasive fungal infections caused by various fungal genera, including Aspergillus, complicate and endanger lives of millions of individuals annually [1]. Aspergillus genera, most frequently Aspergillus fumigatus, are ubiquitous in the environment and cause a wide range of infections in humans, including invasive pulmonary aspergillosis (IPA), chronic pulmonary aspergillosis (CPA), allergic bronchopulmonary aspergillosis (ABPA), chronic rhinosinusitis, fungal asthma, and Aspergillus bronchitis [2,3]. IPA, the most severe manifestation of disease from Aspergillus, is associated with high mortality rates and is a promi